Cytokine receptor zcytor17

• US 7,521,537 B2
• Filed: 10/20/2006
• Issued: 04/21/2009
• Est. Priority Date: 06/26/2000
• Status: Expired due to Term

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Gao, Zeren, Presnell, Scott R., Sprecher, Cindy A., Whitmore, Theodore E., Maurer, Mark F., Kuijper, Joseph L.
• Primary Examiner(s): Bunner; Bridget E
• Assistant Examiner(s): Hamud; Fozia M
• Application Number:
  US11/551,337
• Publication Number:
  US 20070049528A1
• Time in Patent Office: 914 Days
• Field of Search: None
• US Class Current: 530/351
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. An isolated polypeptide comprising amino acid residues 20-732 of SEQ ID NO:

2.

2. The isolated polypeptide of claim 1 wherein the polypeptide comprises amino acid residues 1-732 of SEQ ID NO:

2.

3. An isolated soluble receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO:

2.

4. The isolated soluble receptor polypeptide of claim 3 further comprising a heavy chain constant region of an immunoglobulin.

5. The isolated soluble receptor polypeptide of claim 4 wherein the heavy chain constant region of the immunoglobulin is human Fc4.

6. A composition comprising:

a soluble receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO;

2; and

a pharmaceutically acceptable vehicle.

7. The composition of claim 6 wherein the soluble receptor polypeptide is fused to a heavy chain constant region of an immunoglobulin.

8. The composition of claim 7 wherein the wherein the heavy chain constant region of the immunoglobulin is human Fc4.